Citalopram for pediatric functional abdominal pain: A randomized, placebo-controlled trial

Neurogastroenterology and Motility

Volumn 26, Issue 11, 2014, Pages 1642-1650

  Roohafza, H ^a   Pourmoghaddas, Z ^b   Saneian, H ^b   Gholamrezaei, A ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Poursina Hakim Research Institute   (Iran)

Author keywords

Abdominal pain; Antidepressive agents; Child; Randomized controlled trial; Serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM;

ABDOMINAL PAIN; ADOLESCENT; ANXIETY; CHILD; COMPLICATION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; GASTROINTESTINAL DISEASES; HUMAN; MALE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL;

ABDOMINAL PAIN; ADOLESCENT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; CHILD; CITALOPRAM; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES;

EID: 84907867751     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12444     Document Type: Article

References (26)

1. Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol 2005; 100: 1868-75.
2. Saps M, Seshadri R, Sztainberg M, Schaffer G, Marshall BM, Di Lorenzo C. A prospective school-based study of abdominal pain and other common somatic complaints in children. J Pediatr 2009; 154: 322-6.
3. Dhroove G, Chogle A, Saps M. A million-dollar work-up for abdominal pain: is it worth it? J Pediatr Gastroenterol Nutr 2010; 51: 579-83.
4. Levy RL, Olden KW, Naliboff BD, Bradley LA, Francisconi C, Drossman DA, Creed F. Psychosocial aspects of the functional gastrointestinal disorders. Gastroenterology 2006; 130: 1447-58.
5. Di Lorenzo C, Colletti RB, Lehmann HP, Boyle JT, Gerson WT, Hyams JS, Squires RH, Walker LS etal. Chronic abdominal pain in children: a technical report of the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40: 249-61.
6. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2011; 8: CD003460.
7. Ford AC, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM etal. Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 1350-65; in press. doi: 10.1038/ajg.2014.148.
8. Dekel R, Drossman DA, Sperber AD. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin Investig Drugs 2013; 22: 329-39.
9. Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008; 152: 685-9.
10. Saps M, Youssef N, Miranda A, Nurko S, Hyman P, Cocjin J, Di Lorenzo C. Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders. Gastroenterology 2009; 137: 1261-9.
11. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297: 1683-96.
12. Campo JV, Perel J, Lucas A, Bridge J, Ehmann M, Kalas C, Monk K, Axelson D etal. Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. J Am Acad Child Adolesc Psychiatry 2004; 43: 1234-42.
13. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker LS. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006; 130: 1527-37.
14. Tomlinson D, von Baeyer CL, Stinson JN, Sung L. A systematic review of faces scales for the self-report of pain intensity in children. Pediatrics 2010; 126: e1168-98.
15. Kovacs M. The Children's Depression, Inventory (CDI). Psychopharmacol Bull 1985; 21: 995-8.
16. Reynolds CR, Richmond BO. Factor structure and construct validity of "what I think and feel": the Revised Children's Manifest Anxiety Scale. J Pers Assess 1979; 43: 281-3.
17. Walker LS, Beck JE, Garber J, Lambert W. Children's Somatization Inventory: psychometric properties of the revised form (CSI-24). J Pediatr Psychol 2009; 34: 430-40.
18. Roohafza H, Pirnia A, Sadeghi M, Toghianifar N, Talaei M, Ashrafi M. Impact of nurses clothing on anxiety of hospitalised children. J Clin Nurs 2009; 18: 1953-9.
19. Dehshiri GhR, Najafi M, Shikhi M, Habibi Askarabad M. Investigating primary psychometric properties of children's depression inventory (CDI). J Fam Res 2009; 5: 159-77.
20. National Institute of Mental Health. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 1985; 21: 714-1124.
21. Hammerness PG, Vivas FM, Geller DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr 2006; 148: 158-65.
22. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S, Emmott S, Proffitt V etal. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31.
23. Kuiken SD, Tytgat GN, Boeckxstaens GE. Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders-the clinical evidence. Aliment Pharmacol Ther 2005; 21: 633-51.
24. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130: 1538-51.
25. Kronenberg S, Apter A, Brent D, Schirman S, Melhem N, Pick N, Gothelf D, Carmel M etal. Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol 2007; 17: 741-50.
26. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013; 25: 453-7.